Neural Extracellular Vesicles for Spinal Cord Injury Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for spinal cord injuries, strokes, and neurodegenerative diseases face challenges such as complications from stem cell transplantation, including teratoma formation, adverse immune responses, and inefficient delivery of stem cells to the central nervous system, which can lead to hemorrhages and edema.

Innovation Solution

The use of neural extracellular vesicles (EVs) derived from cultured neural progenitor cells, astrocytes, or mesenchymal stem cells, which are isolated and administered in compositions that may include neurotrophic agents and biocompatible scaffolds, to promote cellular repair and immune modulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If stem cells are transplanted to treat nervous system diseases, then cell replacement and repair can be achieved, but teratoma formation and adverse immune responses occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidteratoma formation and immune response

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and utilizes only the beneficial extracellular vesicles (EVs) from stem cells, separating them from the problematic stem cell components that cause teratoma formation and immune rejection. The EVs contain therapeutic factors while lacking the harmful properties of whole stem cells.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses EVs as a copy or surrogate of stem cell therapy, transferring the therapeutic signaling capabilities of stem cells without using the actual stem cells themselves. The EVs replicate the beneficial paracrine effects of stem cells while avoiding their drawbacks.

Inventive Principle:

Principle #26Copying

2Ease of operation

If stem cells are directly injected into the CNS to treat injuries, then cell delivery can be achieved, but hemorrhages and edema occur during invasive surgery

Engineering Contradiction:

Improvestem cell deliveryVSAvoidhemorrhages and edema

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the therapeutic factors into EVs that can be delivered through less invasive routes, eliminating the need for invasive CNS surgery. The EVs can be administered systemically or locally without causing surgical complications.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The EVs serve as an intermediary carrier that can deliver therapeutic factors to the CNS through blood-brain barrier or other less invasive routes, replacing the need for direct surgical injection of stem cells.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If stem cells are administered systemically to treat CNS diseases, then non-invasive delivery can be achieved, but stem cells lodge in small capillaries and may not reach the disease site

Engineering Contradiction:

Improvesystemic administrationVSAvoiddelivery efficiency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The EVs are much smaller than whole stem cells, allowing them to circulate efficiently through the bloodstream and reach the CNS without getting trapped in capillaries. They replicate the therapeutic delivery function of stem cells with superior circulation properties.

Inventive Principle:

Principle #26Copying

Data Source

PatentUS20250019650A1Neural cell extracellular vesicles

Publication Date: 2025.01.16 ARUNA BIO INC

AI summary

Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative diseases.